COVID-19 and it’s naysayers are attacking Science and Reason. The defenders must suffer the slings and arrows from…
On Apr. 23, 2021, University of Oxford data from the COVID-19 Infection Survey was the first to show…
On Apr. 23, 2021, Inovio Pharma announced that it was planning for a predominantly ex-U.S. Phase 3 trial…
On Apr. 22, 2021, the Strategic Advisory Group of Experts (SAGE) on Immunization annouced updated interim guidance on…
On Apr. 21, 2021, Dynavax Technologies announced Valneva had initiated a pivotal Phase 3 clinical trial for its…
On Apr. 20, 2021, the World Health Organization (WHO) announced that two years on from the launch of…
On Apr. 20, 2021, Moderna announced a new supply agreement with Israel for 2022 whereby Israel also retained…
On Apr. 20, 2021, Johnson & Johnson announced that the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee had…
On Apr. 19, 2021, Pfizer and BioNTech announced supplying an additional 100 million doses of COMIRNATY, the companies…
On Apr. 19, 2021, CureVac and Celonic Group announced their partnership for the production of CureVacï¾’s mRNA-based COVID-19…
On Apr. 15, 2021, Merck announced the discontinuation of development of MK-7110 (formerly known as CD24Fc) for the…
On Apr. 15, 2021, researchers at the University of Oxford reported that the risk of the rare blood…
On Apr. 15, 2021, Inovio Pharmaceuticals announced the results of a study focusing on the human immune responses…
On Apr. 14, 2021, following concern raised around thrombotic events, AstraZeneca offered its reassurance on the safety of…
On Apr. 14, 2021, researchers running the Com-Cov study, launched in February to investigate alternating doses of the…
On Apr. 14, 2021, Moderna announced that results from a preclinical study of the Companyï¾’s COVID-19 variant-specific vaccine…
On Apr. 14, 2021, Novavax announced its participation in an expanded investigator-initiated Phase 2 clinical trial called Comparing…
On Apr. 13, 2021, Moderna announced that new results from a preclinical study of the Companyï¾’s COVID-19 variant-specific…
On Apr. 9, 2021, Regeneron announced that newly updated National Institutes of Health (NIH) COVID-19 treatment guidelines strongly…
On Apr. 9, 2021, Pfizer announced they had requested amendments to the U.S. Emergency Use Authorization (EUA) of…
On Apr. 8, 2021, ImmunityBio reported initial data indicating that a single subcutaneous injection of the companyï¾’s COVID-19…
On Apr. 7, 2021, the NIH announced that a clinical trial was underway to determine whether people who…
On Apr. 7, 2021, the COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS) announed…
On Apr. 7, 2021, Moderna announced publication of antibody persistence data out to 6 months following the second…
On Apr. 6, 2021, Moderna and Catalent announced the expansion of their strategic collaboration to dedicate a new…
On Apr. 5, 2021, Dynavax Technologies announced that Valneva had reported positive initial results for Part A of…
On Apr. 5, 2021, Novavax announced the initiation of crossover arms in two ongoing clinical trials of NVX-CoV2373,…
On Apr. 4, 2021, Emergent BioSolutions announced it had received a contract modification to increase the original task…
On Apr. 1, 2021, Kaiser Permanente Washington Health Research Institute (KPWHRI) announced that an investigational vaccine designed to…
On Mar. 31, 2021, the NIH announced that an investigational vaccine designed to protect against the B.1.351 SARS-CoV-2…